Clinical Education Center

Register now for this live webinar, where Dr Januzzi will discuss how current evidence supports a causal association between low HDL-C (high-density lipoprotein cholesterol) and cardiovascular risk, and that therapeutic targeting of low HDL-C may be beneficial. However, multiple clinical trials for therapies that increase HDL-C levels have failed to produce positive results. These failed clinical trials have led to the consensus that understanding the function of HDL—not just its levels—is needed to determine and develop effective treatment.

We invite you to join us for a discussion on:

• What is known about HDL and its role in atherosclerosis?

• A novel tool that allows for rapid assessment of HDL function for use in clinical practice

• The relation of the HDLfx panel with pCAD score to other cardiovascular risk markers

• A clinical perspective of HDLfx

James L. Januzzi, MD

Hutter Family Professor of Medicine, Harvard Medical School

Cardiologist, Massachusetts General Hospital

Senior Cardiometabolic Faculty, Baim Institute for Clinical Research

Boston, Massachusetts

ASCLS P.A.C.E.^® credit will not be available for this presentation.